Delayed generic introduction under patent application to cause 400 BW of loss.

It is estimated that the delayed market launching of generic drugs caused by the new patent related registration process under the KORUS FTA may generate about 396,800 million won of sales losses for 5 years in the future.

To minimize such an enormous loss the expert recommended for the government to spend more efforts to review the patent applications more carefully.

According to the...